ISSN: 2457-0400

Impact Factor: 7.675

WORLD JOURNAL OF ADVANCE HEALTHCARE RESEARCH

www.wjahr.com

Volume: 10, Issue: 7

Page N. 38-43

Year: 2026

Review Article

Coden USA: WJAMA3

DRUG DISCOVERY AND DEVELOPMENT PROCESS: A COMPREHENSIVE REVIEW

Parag Chandrakant Patil*[1], Harshali Rajendra Patil[2], Nilesh Rajendra Patil[3], Harshad Shiva Kadam[4], Sughosh Upasani[5]

[1,2]Department of Quality Assurance, Shri Gulabrao Deokar College of Pharmacy, Jalgaon, 425003, Maharashtra, India.
[3,4]Department of Quality Assurance, Mahatma Gandhi Vidya Mandir College of Pharmacy, Panchavati, Nashik, 422003, Maharashtra, India.
[5]Department of Pharmacy Practice, SES's R. C. Patel Institute of Pharmacy, Shirpur, 425405, Dhule, Maharashtra, India.

Article Received: 01 June 2026 **Article Revised:** 22 June 2026 **Article Published:** 01 July 2026

***Corresponding Author: Parag Chandrakant Patil**

Department of Quality Assurance, Shri Gulabrao Deokar College of Pharmacy, Jalgaon, 425003, Maharashtra, India. **DOI:** https://doi.org/10.5281/zenodo.21022182

How to cite this Article: Parag Chandrakant Patil*[1], Harshali Rajendra Patil[2], Nilesh Rajendra Patil[3], Harshad Shiva Kadam[4], Sughosh Upasani[5]. (2026). Drug Discovery and Development Process: A Comprehensive Review. World Journal of Advance Healthcare Research, 10(7), 38–43.

ABSTRACT

This abstract provides an in-depth exploration of drug development, from historical perspectives to modern challenges and emerging trends. It begins by tracing the evolution of drug development over centuries, highlighting the pivotal role of pharmacy and regulatory oversight. The abstract emphasizes the multifaceted nature of drug development, involving collaboration across scientific disciplines and various stages, from preclinical to post-market monitoring. The challenges inherent in drug development, such as high costs, lengthy timelines, and regulatory hurdles, are thoroughly examined. Despite these challenges, the abstract underscores the importance of drug development in addressing unmet medical needs and improving public health. Furthermore, the abstract delves into specific aspects of drug development, including preclinical research and discovery, clinical trial methodologies, and successes and challenges in the field. It also discusses emerging trends, such as precision medicine, digitalization, and the role of artificial intelligence and machine learning. Overall, this abstract is providing a comprehensive overview of drug development, highlighting its significance, challenges, and future directions in advancing healthcare.

KEYWORDS: Drug development, Regulatory oversight, Preclinical research, Artificial intelligence, Emerging trends.

INTRODUCTION

Drug discovery and development is a multidisciplinary and highly regulated process that transforms a scientific concept into a safe and effective therapeutic product for human use. It integrates pharmaceutical sciences, medicinal chemistry, molecular biology, pharmacology, toxicology, clinical medicine, bioinformatics, regulatory science, and manufacturing technologies. The primary objective of this process is to identify promising therapeutic candidates, evaluate their safety and efficacy through systematic preclinical and clinical investigations, and obtain regulatory approval before commercialization. The entire process is time-consuming, expensive, and scientifically demanding, often requiring more than 10–15 years of research and billions of dollars in investment before a new drug reaches the market. Recent advancements in precision medicine, genomics, proteomics, metabolomics, artificial intelligence (AI), machine learning (ML), computational drug design, and translational medicine have significantly transformed modern drug development. These technologies enable researchers to identify disease-specific biomarkers, predict therapeutic responses, optimize drug candidates, and improve clinical outcomes. Precision medicine, in particular, focuses on tailoring therapeutic interventions according to individual genetic, molecular, and environmental characteristics, thereby improving efficacy while minimizing adverse effects.[1–6]



The conventional drug discovery process begins with target identification and validation, followed by lead compound identification, lead optimization, preclinical evaluation, and extensive clinical trials. Each stage involves rigorous scientific assessment to ensure that the candidate drug demonstrates acceptable pharmacological activity, toxicity profile, pharmacokinetics, pharmacodynamics, and therapeutic efficacy. Regulatory authorities such as the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Central Drugs Standard Control Organization (CDSCO) in India play a critical role in evaluating scientific evidence before granting approval for human use.[7–13] Drug development has also evolved with innovations in formulation science and novel drug delivery systems. Technologies such as nanoparticles, self-emulsifying drug delivery systems (SEDDS), microemulsions, nanotechnology, targeted drug delivery, and biologics have improved drug bioavailability, therapeutic efficacy, and patient compliance.[16–20] Furthermore, biomarker-based drug development and regulatory qualification of biomarkers have accelerated clinical decision-making and personalized medicine.[21] Despite remarkable technological progress, the development of new drugs remains associated with numerous challenges, including high research costs, low success rates, ethical considerations, regulatory complexities, and post-marketing safety concerns. The integration of AI, computational biology, omics technologies, and patient-centric product development is expected to address many of these challenges and accelerate future drug discovery.[19,24,25] This review discusses the complete drug discovery and development process, including preclinical studies, clinical trials, regulatory requirements, drug approval procedures in India, and post-marketing surveillance. It also highlights the role of emerging technologies and evolving regulatory frameworks in improving the efficiency and quality of pharmaceutical development.

DISCUSSION

Drug discovery begins with identifying a biological target associated with a specific disease. The target may be a receptor, enzyme, ion channel, transporter, nucleic acid, or signaling pathway that plays a crucial role in disease progression. Once validated, researchers identify lead compounds capable of interacting with the target to produce the desired therapeutic effect. Modern approaches combine high-throughput screening, computational chemistry, molecular docking, structure-based drug design, artificial intelligence, and systems biology to improve the efficiency of lead identification.[1–6,19] Lead optimization involves modifying the chemical structure of identified compounds to improve potency, selectivity, pharmacokinetic properties, metabolic stability, and safety. During this stage, medicinal chemists evaluate structure-activity relationships (SAR), optimize physicochemical properties, and minimize toxicity while maximizing therapeutic activity. The optimized molecule then progresses to preclinical evaluation. Preclinical studies are performed in both laboratory and animal models to assess pharmacological activity, mechanism of action, pharmacokinetics, toxicology, and safety. These studies include acute toxicity, subacute toxicity, chronic toxicity, reproductive toxicity, carcinogenicity, mutagenicity, genotoxicity, and safety pharmacology. Information generated during preclinical testing provides evidence supporting the initiation of human clinical trials. Ethical considerations remain fundamental during animal experimentation, requiring compliance with national and international animal welfare regulations.[10,22] Following successful preclinical evaluation, sponsors submit an Investigational New Drug (IND) application or equivalent regulatory dossier containing preclinical data, manufacturing information, quality specifications, investigator brochures, and proposed clinical protocols. Regulatory authorities review these submissions before granting permission to initiate clinical trials. Clinical development is divided into four sequential phases.



Phase I trials are conducted in a small number of healthy volunteers to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and dose escalation. These studies establish the maximum tolerated dose and identify early adverse effects. Although primarily designed for safety evaluation, Phase I studies also generate important information regarding drug metabolism and elimination.[26] Phase II clinical trials involve patients suffering from the target disease. These studies evaluate therapeutic efficacy, determine optimal dosage, further assess safety, and establish proof of concept. Randomized controlled designs are frequently employed to compare different dosage regimens and assess preliminary clinical benefit. Phase III trials represent the largest and most comprehensive stage of clinical development. Thousands of patients across multiple clinical centers participate in randomized controlled studies designed to confirm efficacy, evaluate safety, compare new treatments with existing standards, and generate evidence for regulatory approval. Data collected during Phase III forms the foundation of the New Drug Application (NDA) submitted to regulatory authorities.[7,13] After marketing approval, Phase IV or post-marketing surveillance studies continue throughout the product's commercial life. These studies identify rare adverse drug reactions, long-term safety issues, drug interactions, effectiveness in broader populations, and opportunities for new therapeutic indications. Continuous pharmacovigilance plays a critical role in protecting public health by monitoring real-world drug performance.[29] Regulatory approval represents one of the most critical stages of drug development. Different countries follow specific regulatory pathways while adhering to internationally accepted scientific standards. In India, the Central Drugs Standard Control Organization (CDSCO), functioning under the Drugs Controller General of India (DCGI), regulates clinical trials, new drug approval, import, manufacture, and post-marketing surveillance. Before initiating clinical trials in India, sponsors are required to submit comprehensive documentation that includes chemistry and manufacturing information, pharmacology and toxicology data, animal study reports, published clinical trial reports, proposed study protocols, investigator brochures, informed consent documents, trial duration, drug master file information, and undertakings regarding reporting of serious adverse events. Bioavailability and bioequivalence (BABE) studies must also comply with established BABE guidelines. Comprehensive information regarding worldwide regulatory status, product labeling, testing protocols, prescription information, and marketing authorization in other countries must accompany the application.[6] The requirement for local clinical trials depends upon the international approval status of the drug. When a drug has already been approved in several countries, Phase III studies are generally required before approval in India. Phase I trials are permitted only under specific circumstances, particularly when the drug addresses diseases of special public health importance such as malaria or tuberculosis.[6] The Drugs and Cosmetics Rules, 1945, govern regulatory approval procedures in India. Important provisions include Rule 122-A governing permission to import new drugs, Rule 122-B concerning manufacturing approval, Rule 122-D regulating fixed-dose combinations, Rule 122-DA concerning permission for clinical trials involving investigational new drugs, and Rule 122-DAB relating to compensation in cases of clinical trial-related injury or death. These provisions strengthen participant protection and improve regulatory oversight.[26] The clinical trial approval process in India classifies studies into two categories. Category A includes drugs already approved in countries with mature regulatory systems such as the United States, United Kingdom, Switzerland, Australia, Canada, Germany, South Africa, Japan, and the European Union. Such applications are generally fast-tracked and approved within approximately eight weeks. Category B includes all other applications requiring more extensive scientific evaluation, with approval timelines extending to approximately sixteen to eighteen weeks.[27] Applications submitted to the DCGI must include Chemistry, Manufacturing and Control (CMC) documentation, animal pharmacology data, toxicology reports, investigator brochures, informed consent forms, and detailed study protocols. Simultaneously, the protocol must be reviewed and approved by an Institutional Ethics Committee. Clinical trials can

commence only after obtaining approval from both the DCGI and the Ethics Committee.[27] India has increasingly harmonized its regulatory requirements with international standards by adopting the Common Technical Document (CTD) format. This harmonization facilitates standardized submission of quality, safety, and efficacy information, thereby improving regulatory efficiency and international acceptance of pharmaceutical dossiers.[28] Recent developments in pharmaceutical sciences have significantly influenced drug discovery strategies. Artificial intelligence and machine learning enable virtual screening of millions of compounds, prediction of molecular interactions, optimization of drug candidates, identification of biomarkers, and prediction of toxicity profiles before laboratory experimentation.[19,24] Similarly, genomics, proteomics, metabolomics, and multi-omics technologies have expanded opportunities for precision medicine by enabling personalized therapeutic approaches based on molecular characteristics.[1–6] Novel drug delivery systems have also transformed pharmaceutical development. Nanotechnology-based carriers, polymeric nanoparticles, liposomes, self-emulsifying drug delivery systems, nasal drug delivery, and targeted drug delivery improve drug solubility, stability, bioavailability, controlled release, and tissue-specific targeting while minimizing systemic toxicity.[16–20] Biomarkers have emerged as essential tools throughout drug development. They facilitate patient selection, early diagnosis, monitoring of disease progression, prediction of therapeutic response, assessment of treatment efficacy, and regulatory decision-making. Biomarker qualification has become an integral component of precision medicine and translational research.[5,15,21] Ethical considerations remain central to every phase of drug development. Protection of human participants requires informed consent, independent ethical review, confidentiality, scientific validity, risk-benefit assessment, and continuous monitoring of adverse events. Regulatory agencies have strengthened guidelines to ensure transparency, participant safety, and accountability throughout clinical development.[10,22] Patient-centric drug development has become another important paradigm in pharmaceutical research. Modern regulatory agencies increasingly encourage incorporation of patient preferences, quality-of-life measures, real-world evidence, and patient-reported outcomes into drug development programs. Such approaches improve therapeutic adherence and clinical outcomes while supporting regulatory decision-making.[23] Finally, post-marketing surveillance represents a continuous process of monitoring drug safety after commercialization. The FDA Adverse Event Reporting System (FAERS) enables healthcare professionals, manufacturers, and patients to report adverse events associated with approved medicines. Continuous safety monitoring facilitates timely identification of rare toxicities, label modifications, risk management strategies, and product withdrawal when necessary.[29]

CONCLUSION

Drug discovery and development is a comprehensive scientific, clinical, and regulatory process requiring collaboration among researchers, clinicians, pharmaceutical industries, regulatory authorities, and healthcare professionals. From target identification and lead optimization to preclinical evaluation, clinical trials, regulatory review, manufacturing, and post-marketing surveillance, every stage contributes to ensuring that new medicines are safe, effective, and of high quality. The integration of precision medicine, artificial intelligence, biomarker research, multi-omics technologies, and advanced drug delivery systems has transformed traditional pharmaceutical development into a more efficient, personalized, and evidence-based discipline. These innovations are expected to shorten development timelines, reduce costs, improve success rates, and enhance patient outcomes. In India, new drug approval is governed by CDSCO under the Drugs and Cosmetics Rules, 1945. Regulatory requirements emphasize scientific evidence, ethical conduct, participant safety, and compliance with Schedule Y. Clinical trial applications, manufacturing approvals, bioavailability studies, and post-marketing monitoring collectively ensure that pharmaceutical products meet acceptable standards before entering the market. The drug approval process generally consists of two major stages: permission to conduct clinical trials and marketing authorization following successful demonstration of quality, safety, and efficacy. Clinical studies and supporting documentation should comply with the provisions of Schedule Y and relevant regulatory rules, particularly Rules 122-A, 122-B, 122-D, and 122-DA. Continuous pharmacovigilance and post-marketing surveillance further strengthen public confidence by ensuring long-term monitoring of approved medicines. Overall, successful drug development depends upon scientific innovation, ethical responsibility, regulatory compliance, and continuous evaluation throughout the product life cycle. Continued advances in pharmaceutical science and regulatory harmonization are expected to accelerate the discovery of safer, more effective, and patient-centered therapies in the future.

REFERENCES

1. De Maria Marchiano R., Di Sante G., Piro G., Carbone C., Tortora G., Boldrini L., Pietragalla A., Daniele G., Tredicine M., Cesario A., et al. Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go. J. Pers. Med., 2021; 11: 216. doi: 10.3390/jpm11030216. [DOI] [PMC free article] [PubMed] [Google Scholar]
2. Tebani A., Afonso C., Marret S., Bekri S. Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations. Int. J. Mol. Sci., 2016; 17: 1555. doi: 10.3390/ijms17091555. [DOI] [PMC free article] [PubMed] [Google Scholar]

3. Ahmed Z. Precision Medicine with Multi-Omics Strategies, Deep Phenotyping, and Predictive Analysis. Prog. Mol. Biol. Transl. Sci., 2022; 190: 101–125. doi: 10.1016/BS.PMBTS.2022.02.002. [DOI [PubMed] [Google Scholar]
4. Kwon Y.W., Jo H.S., Bae S., Seo Y., Song P., Song M., Yoon J.H. Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery. Front. Med., 2021; 8: 747333. doi: 10.3389/fmed.2021.747333. [DOI] [PMC free article] [PubMed] [Google Scholar]
5. Giannitsis E., Katus H.A. Biomarkers for Clinical Decision-Making in the Management of Pulmonary Embolism. Clin. Chem., 2017; 63: 91–100. doi: 10.1373/clinchem.2016.255240. [DOI] [PubMed] [Google Scholar]
6. Wafi A., Mirnezami R. Translational –Omics: Future Potential and Current Challenges in Precision Medicine. Methods, 2018; 151: 3–11. doi: 10.1016/j.ymeth.2018.05.009. [DOI] [PubMed] [Google Scholar]
7. Herink MC, Irwin AN, Zumach GM. FDA Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals. Pharmacotherapy, 2018; 38(9): 967-80.
8. Hurley R. Government must boost spending on drug dependency services, says landmark review. BMJ. 2021; 374: n1758. Saneja A, Kumar R, Mintoo MJ, Dubey RD, Sangwan PL, Mondhe DM, et al. Gemcitabine and betulinic acid co-enlcapsulated PLGA-PEG polymer nanoparticles efficacy of cancer chemotherapy. Mater Sci Eng C Mater Biol Appl., 2019; 98: 764-771.
9. Sun R, Fei F, Wang M, Jiang J, Yang G, Yang N, et al. Integration of metabolomics and machine learning revealed tryptophan metabolites are sensitive biomarkers of pemetrexed efficacy in non-small cell lung cancer. Cancer Med., 2023; 12(18): 19245-19259.
10. Djordjević D, Paul A, McFadyen J, Anderson A. Ethical challenges and opportunities in the development and approval of novel therapeutics for rare diseases. J Med., 2023; 7: 275508342311775.
11. Iqra B, Usman DB, Syed AHM. New challenges in drug discovery. Novel Platforms for Drug Delivery Applications. Woodhead Publishing Series in Biomaterials, 2023; 619-43.
12. Gummadi M, Koushik Y. Conventional Regulatory Submission Drawbacks and Strategies to Avoid Them. J Pharma Drug Regulatory Affairs, 2023; 5(1): 14-21.
13. Yildirim, O., Gottwald, M., Schüler, P., and Michel, M. C. Opportunities and challenges for drug development: Public-private partnerships, adaptive designs and big data. Front. Pharmacol, 2016; 7: 461. doi:10.3389/fphar.2016.00461.
14. Lang, J., Vincent, L., Chenel, M., Ogungbenro, K., and Galetin, A. Impact of hepatic CYP3A4 ontogeny functions on drug-drug interaction risk in pediatric physiologically-based pharmacokinetic/pharmacodynamic modeling: Critical literature review and ivabradine case study. Clin. Pharmacol. Ther., 2021; 109: 1618–1630. doi:10.1002/cpt.2134.
15. Mokondjimobe E., Longo-Mbenza B., Akiana J., Ndalla U.O., Dossou-Yovo R., Mboussa J., Parra H.J. Biomarkers of Oxidative Stress and Personalized Treatment of Pulmonary Tuberculosis: Emerging Role of Gamma-Glutamyltransferase. Adv. Pharmacol. Sci., 2012.
16. G. Tiwari, R. Tiwari, B. Sriwastawa, L. Bhati, S. Pandey, P. Pandey, S.K. Bannerjee Drug delivery systems: an updated review Int. J. Pharm. Investig., 2012; 2: 2-11.
17. M.A. Rahman, A. Hussain, M.S. Hussain, M.A. Mirza, Z. Iqbal Role of excipients in successful development of self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS) Drug Dev. Ind. Pharm., 2013; 39: 1-19.
18. K. Rajpoot, M. Tekade, V. Pandey, S. Nagaraja, S. Youngren-Ortiz, R. Tekade Self-microemulsifying drug-delivery system: ongoing challenges and future ahead, in, 2019; 393-454.
19. Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R., and Kumar, P. Artificial intelligence to deep learning: Machine intelligence approach for drug discovery. Mol. Divers, 2021; 25: 1315–1360. doi:10.1007/s11030-021-10217-3.
20. N.R. Hussein, H.K. Omer, A.M.A. Elhissi, W. Ahmed W. Ahmed, D.A. Phoenix, M.J. Jackson, C.P.B.T.-A. in M., S.E. Charalambous (Eds.), Chapter 15 - Advances in Nasal Drug Delivery Systems, Academic Press, 2020; 279-311, 10.1016/B978-0-12-819712-7.00015-2.
21. Hendrikse N.M., Llinares Garcia J., Vetter T., Humphreys A.J., Ehmann F. Biomarkers in Medicines Development—From Discovery to Regulatory Qualification and Beyond. Front. Med., 2022; 9: 878942. doi: 10.3389/fmed.2022.878942. [DOI] [PMC free article] [PubMed] [Google Scholar].
22. Djordjević D, Paul A, McFadyen J, Anderson A. Ethical challenges and opportunities in the development and approval of novel therapeutics for rare diseases. J Med., 2023; 7: 275508342311775.
23. Opportunities to include patient-centric product design in industrial medicines development to improve therapeutic goals. Brit J Clin Pharmacol, 2020; 86(10): 2020-7.
24. Khadela A, Popat S, Ajabiya J, Valu D, Savale S, Chavda VP. AI, ML and Other Bioinformatics Tools for Preclinical and Clinical Development of Drug Products. Bioinformatics Tools for Pharmaceutical Drug Product Development. Wiley, 2023; 255-84.
25. Sobti RC, Kumari M, Singhla M, Bhandari R. Emerging Technologies: Gateway to Understand Molecular Insight of Diseases, Newer Drugs, Their

Design, and Targeting. Biomedical Translational Research. Springer, 2022; 3-15.
26. Bashir SF, Meena S, Kumar G. Basics of the Drug Development Process. In Current Trends in the Identification and Development of Antimicrobial Agents. Bentham Science Publisher, 2023; 68-104.
27. Raguzin EV, Yudin MA, Glushenko DD, Vengerovich NG, Raguzina OG, Pechurina TB, et al. Analysis and Evaluation of Modern Approaches to Development of Medical Drugs Using Micro- and Nanotechnologies. I. P. Pavlov Russian Med Biological Herald, 2022; 30(3): 397-410.
28. Baile SB, Hadia R, Kardani S, Patel S, Patel K, Dash D. Anti-diabetic Plant Bioactive Compounds: Modern Drug Development from Traditional Herbal Medicine. In book: Multidisciplinary Approaches in Pharmaceutical Sciences, 2023; 164-81.
29. Sperber N.R., Dong O.M., Roberts M.C., Dexter P., Elsey A.R., Ginsburg G.S., Horowitz C.R., Johnson J.A., Levy K.D., Ong H., et al. Strategies to Integrate Genomic Medicine into Clinical Care: Evidence from the IGNITE Network. J. Pers. Med., 2021; 11: 647. doi: 10.3390/jpm11070647.